CRISPR Therapeutics AG (CRSP) Other financing activities (2017 - 2026)

CRISPR Therapeutics AG (CRSP) has 10 years of Other financing activities data on file, last reported at $6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 197.2% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2026 stood at $32.0 million (up 291.85% YoY), and the FY2025 full-year result was $27.9 million, down 10.72% from the prior year.
• Other financing activities rose to $6.2 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $25.2 million in Q1 2024 to a low of $546000.0 in Q2 2024.
• A 5-year average of $7.8 million and a median of $5.4 million in 2023 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities plunged 96.74% in 2024 and surged 413.09% in 2025, its largest moves.
• Tracing CRSP's Other financing activities over 5 years: stood at $2.5 million in 2022, then surged by 150.93% to $6.2 million in 2023, then slumped by 69.17% to $1.9 million in 2024, then surged by 156.81% to $4.9 million in 2025, then advanced by 25.09% to $6.2 million in 2026.
• Business Quant data shows CRSP's Other financing activities at $6.2 million in Q1 2026, $4.9 million in Q4 2025, and $18.7 million in Q3 2025.